BTIG affirms Progenics Pharmaceuticals (Nasdaq: PGNX) at Buy with a price target of $9 after Progenics and Valeant Pharma (NYSE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral RelistorJuly 20, 2016 10:22 AM Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & CompanyJuly 20, 2016 9:16 AM Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTORJuly 20, 2016 8:10 AM Rodman & Renshaw Reiterates Buy Rating on Valeant (VRX) July 20, 2016 8:02 AM Progenics (PGNX) volatility elevated into FDA approval of constipation treatment July 20, 2016 5:43 AM Valeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTORJuly 19, 2016 6:06 PM Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer PainJuly 19, 2016 6:04 PM